Last updated on December 2018

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
  • Age: Between 50 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Weight greater than or equal to (>=) 40 kg to less than or equal to (<=) 150 kilogram (kg)
  • Medically appropriate for postoperative anticoagulant prophylaxis as determined by the investigator
  • Has undergone an elective primary unilateral total knee replacement (TKR)
  • Before randomization, a woman must not be of childbearing potential defined as postmenopausal (defined as no menses for 12 months without an alternative medical cause) and/ or permanently sterile (include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy)
  • Contraceptive use by men should be consistent with local regulations regarding the use of contraceptive methods for participant participating in clinical studies

Exclusion Criteria:

  • Any condition for which the use of apixaban is not recommended in the opinion of the investigator
  • Bilateral, revision or unicompartmental procedure
  • Known or suspected hypersensitivity or intolerance to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or any of the excipients of JNJ-64179375
  • Unable to undergo venography
  • Known previous deep vein thrombosis (DVT) in either lower extremity

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.